Insider buying last 90 days
No open-market insider purchases were filed for LBRX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every LBRX insider filing, plotted on the chart in Gekko.Open LBRX in Gekko
NASDAQ: LBRX
LB Pharmaceuticals (LBRX) Stock Analysis & Forecast
Oct 12 close
$35.93−1.29 (−3.5%)
Gekko Brief
Oct 12 closeLB Pharmaceuticals closed at $35.93 on 12 October 2026, -3.5% on the day. The price sits between the 50-day ($43.59) and 200-day ($31.34) moving averages, inside a 52-week range of $14.32 to $50.16. The GekkoIndex reads 67.4, in the Accumulation zone, down 5.8 points over five sessions. Gekko Fair Value is $41.61, so the price is 13.7% below it.
The next earnings report is due on 5 November 2026, 24 days away. Over the last 4 reports the company beat the earnings estimate 1 times, with an average move of 1.2% across the report.
10 firms rate the stock: 9 buy, 1 hold and 0 sell, with a consensus target of $57.30. A typical daily move is about 6.3%, and a typical 20-day move about 10.9%. On the swing-trade checklist, 2 items read supportive and 1 reads as a headwind (earnings risk).
A plain summary of the figures as of the Oct 12, 2026 close.
LB Pharmaceuticals price vs fair value
Close $35.93200-day averageGekko Fair Value $41.61
LB Pharmaceuticals quick facts
- Market cap
- $1.03B
- P/E ratio
- 346.1
- Forward P/E
- —
- EPS, TTM
- $0.10
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- —
- Volume
- 491,507 avg 424,074
- 1-year return
- +129.7%
- Typical daily move
- ±6.3%
- Typical 20-day move
- ±10.9%
- 50-day average
- $43.59
- 200-day average
- $31.34
- Next earnings
- Nov 5
- Shares outstanding
- 32.26M
LB Pharmaceuticals swing-trade checklist
LB Pharmaceuticals scores 2 supportive, 1 mixed and 1 headwind across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $35.93 sits between the 50-day ($43.59) and 200-day ($31.34) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
67.4, Accumulation
Reading 67.4 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
13.7% below
Price is 13.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
LB Pharmaceuticals stock chart and price history
LB Pharmaceuticals closed at $35.93 on Oct 12, 2026, +129.7% over the past year, inside a 52-week range of $14.32 to $50.16.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −19.5%
- 3 months
- +12.2%
- 6 months
- +41.3%
- 1 year
- +129.7%
The full LBRX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LBRX in Gekko
Follow LB Pharmaceuticals through every session
Put LBRX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track LBRX in GekkoFree for 7 days. No credit card required.
About LB Pharmaceuticals
LB Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for neuropsychiatric disorders, among them schizophrenia and bipolar depression. Rather than selling approved medicines, the company devotes its efforts to research and testing candidates meant to address these conditions, with the aim of eventually bringing such treatments to patients who need them.
The centerpiece of its work is LB-102, the company's lead investigational drug. LB-102 is a methylated variant of amisulpride, and it stands as the main asset in the company's development pipeline. The company's activities are organized around advancing this candidate through the stages of clinical development, rather than around existing commercial sales, reflecting its position as a firm still in the research and testing phase of bringing a product forward.
Shares of LB Pharmaceuticals trade on the NASDAQ under the ticker LBRX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- lbpharma.us
LB Pharmaceuticals GekkoIndex: the smart money zone
LB Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.4, in the Accumulation zone, down 5.8 points over five sessions.
67.4Accumulation
Down 5.8 points over five sessions, from the Buying zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 17 | −3.5% | +0.7% | ||
| Accumulation (current zone) | 38 | +0.8% | +18.0% | ||
| Neutral | 187 | +2.5% | +7.7% | ||
| Distribution | 25 | +0.5% | +8.1% | ||
| Selling | 0 | Not available | |||
Average LBRX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the LBRX price, zone by zone.Track LBRX in Gekko
Is LB Pharmaceuticals stock overvalued? Gekko Fair Value
LB Pharmaceuticals trades 13.7% below Gekko Fair Value of $41.61, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what LB Pharmaceuticals shares are worth, recalculated every trading day.
$41.61
Gekko Fair Value, Oct 10, 2026
13.7% Undervalued
At the end of Aug 2026 the price was 43.0% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open LBRX in Gekko
LB Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for LB Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in LBRX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for LBRX, plotted on the chart in Gekko.Open LBRX in Gekko
LB Pharmaceuticals earnings: next date and track record
LB Pharmaceuticals reports on Nov 5, 2026 (24 days away), and beat the EPS estimate in 1 of its last 4 reports.
Next earnings report
Nov 5, 2026
24 days away
- EPS estimate
- −$1.62
1 of 4reports beat the EPS estimate
±1.2%average move across the report
0 of 3reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 11, 2026 | −$1.71 est −$0.80 | — | −1.0% |
| May 12, 2026 | −$0.67 est −$0.70 | — | −1.2% |
| Mar 26, 2026 | −$0.45 est −$0.32 | — | −1.5% |
| Sep 8, 2025 | −$1.44 | — | — |
| Sep 3, 2025 | −$1.44 est $0.00 | — | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
LB Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for LB Pharmaceuticals is $57.30, +59.5% from the last close, from 10 firms rating the stock in the last 90 days.
$57.30consensus 12-month target, +59.5% from the last close
Now $35.93Avg $57.30
Low $35High $80
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | Guggenheim | $80 | +122.7% |
| Oct 12 | H.C. Wainwright | $60 | +67.0% |
| Oct 9 | Canaccord Genuity | $65 | +80.9% |
| Oct 5 | Guggenheim | $80 | +122.7% |
| Oct 5 | Guggenheim | $80 | +122.7% |
+18.0%average 20-day move after past Accumulation readings
±6.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
LB Pharmaceuticals market cap and key statistics
LB Pharmaceuticals’s market cap is $1.03B, with a P/E ratio of 346.1 and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $1.03B
- P/E ratio
- 346.1
- EPS, TTM
- $0.10
- Gekko Fair Value
- $41.61
Trading
- Volume
- 491,507
- Avg volume, 20 days
- 424,074
- 52-week high
- $50.16
- 52-week low
- $14.32
- Shares outstanding
- 32.26M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -50%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Typical daily move
- ±6.3%
- Typical 20-day move
- ±10.9%
LB Pharmaceuticals stock news this week
Coverage of LB Pharmaceuticals this week reads positive: 9 positive, 0 neutral and 4 negative headlines.
- LB Pharmaceuticals shares maintained at buy by H.C. WainwrightInvesting.com, Oct 12
- H.C. Wainwright Reiterates Buy Rating on LB Pharmaceuticals Inc (LBRX)StreetInsider, Oct 12
- LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP CongressGlobeNewswire, Oct 10
- LB Pharmaceuticals (NASDAQ:LBRX) Upgraded to "Strong-Buy" at Canaccord Genuity GroupMarketBeat, Oct 10
- LB Pharmaceuticals grants stock options to new CMO and CFO as inducement under Nasdaq rulesPluang, Oct 9
- LB Pharmaceuticals Grants Inducement Equity Awards to New Chief Medical Officer and Chief Financial OfficerQuiver Quantitative, Oct 9
LB Pharmaceuticals peers
LB Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
LB Pharmaceuticals stock FAQ
What is LB Pharmaceuticals’s market cap?
LB Pharmaceuticals’s market cap is $1.03B at the Oct 12, 2026 close of $35.93, with 32.26M shares outstanding. The shares trade on a P/E ratio of 346.1.
What is the LB Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for LB Pharmaceuticals is $57.30, +59.5% from the last close. Of the 10 firms that rated the stock in the last 90 days, 9 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is LB Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate LB Pharmaceuticals is undervalued: the Oct 12, 2026 close of $35.93 is 13.7% below Gekko Fair Value of $41.61. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does LB Pharmaceuticals report earnings next?
LB Pharmaceuticals is expected to report on Nov 5, 2026 (24 days away). Analysts expect earnings of −$1.62 per share. LB Pharmaceuticals beat the earnings estimate in 1 of its last 4 reports, moving 1.2% on average across the report.
What is LB Pharmaceuticals’s 52-week high and low?
LB Pharmaceuticals’s 52-week high is $50.16 and its 52-week low is $14.32; it closed at $35.93 on Oct 12, 2026, +129.7% over the past year.
Is LB Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 4 items with data read as supportive (gekkoindex and fair value), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See LB Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.